In addition, a limited study of five CRC cell lines found that those that were MRE11/RAD50-deficient were more sensitive to irinotecan [21], but did not determine whether irinotecan resistance could be restored by complementing the MRE11/RAD50-deficiency/. This evidence concerns the gene MRE11 and colorectal carcinoma.